Regulatory factor X5 promotes hepatocellular carcinoma progression by transactivating tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta and suppressing apoptosis
Hepatocellular carcinoma (HCC)—the most common form of liver cancer—ranks as the third leading cause of cancer-related death globally. Despite advances in surgery, chemotherapy, and immunotherapy, the 5-year survival rate for HCC remains below 20% in many countries. A key barrier to better treatments is our limited understanding of the molecular pathways that drive HCC growth. A 2019 study led by researchers from Peking University People’s Hospital, Jiangsu University, and Guilin Medical University’s Affiliated Hospital sheds light on one such pathway: a protein called regulatory factor X5 (RFX5) and its target gene YWHAQ (14-3-3 tau), which work together to help HCC cells avoid death and grow uncontrollably.
RFX5 Is Overexpressed in HCC and Drives Tumor Growth
RFX5 is a transcription factor—a protein that turns genes on or off—best known for regulating immune system genes (like those for MHC class II, which help immune cells recognize pathogens). But previous research from the team showed RFX5 is overexpressed in HCC tumors, with no clear link to its immune role. To uncover RFX5’s function in cancer, the team analyzed data from The Cancer Genome Atlas (TCGA), a global database of cancer genetics, and conducted lab experiments with HCC cell lines and mouse models.
First, they found that RFX5 is frequently amplified (has extra copies of its DNA) in HCC: about 25% of patients had 1.5x more RFX5 DNA in their tumors than in healthy liver tissue. This amplification directly correlated with higher RFX5 mRNA levels—meaning more copies of the gene led to more RFX5 protein being made. In fact, RFX5 mRNA was 7x higher in HCC tumors than in normal tissue, and protein levels were elevated in 71% of tumor samples tested via immunohistochemistry (IHC).
But does RFX5 actually cause HCC growth? The team used two techniques to block RFX5 in HCC cells—short hairpin RNA (shRNA) and CRISPR/Cas9 gene editing—and found that reducing RFX5 levels drastically slowed cell growth in lab dishes (clonogenic assays) and in mice (xenograft models). For example, mice implanted with RFX5-knockdown MHCC-97H cells developed tumors that were 50% smaller and lighter than control tumors after 50 days. Conversely, overexpressing RFX5 in HepG2 cells increased colony formation by 30%. These results proved RFX5 is not just a “bystander” in HCC—it’s an essential driver of tumor growth.
YWHAQ: A Critical Target of RFX5 in HCC
Transcription factors act by binding to DNA and turning on downstream genes. To find RFX5’s targets in HCC, the team used chromatin immunoprecipitation sequencing (ChIP-seq)—a technique that maps where proteins bind to DNA—in HepG2 cells. They discovered a strong RFX5 binding peak in the promoter region (the “on/off switch”) of YWHAQ, a gene that makes the 14-3-3 tau protein.
14-3-3 proteins are a family of “scaffold” proteins that regulate cell processes like growth, division, and death by interacting with other proteins. YWHAQ (14-3-3 tau) is already linked to breast and lung cancer, but its role in HCC was unknown. The team validated RFX5’s control of YWHAQ in three ways:
- ChIP-PCR: They confirmed RFX5 binds to the YWHAQ promoter in multiple HCC cell lines.
- Luciferase assays: When they co-expressed RFX5 and a YWHAQ promoter-luciferase construct in HEK293T cells, luciferase activity (a marker of gene expression) doubled—proving RFX5 turns on YWHAQ transcription.
- Gain/loss of function: Knocking down RFX5 reduced YWHAQ mRNA and protein levels; overexpressing RFX5 increased them.
The link between RFX5 and YWHAQ wasn’t just molecular—it was clinical, too. TCGA data showed YWHAQ mRNA levels were 8x higher in HCC tumors than in normal tissue, and YWHAQ expression tightly correlated with RFX5 (r=0.73, p<0.001). Worse, patients with high YWHAQ levels had shorter recurrence-free survival (time without cancer coming back) than those with low levels—a sign YWHAQ drives aggressive HCC.
RFX5-YWHAQ Blocks Apoptosis via the p53 Pathway
Why does YWHAQ matter for HCC? The team focused on apoptosis—programmed cell death—a process cancer cells must avoid to grow. They treated HCC cells with Dactinomycin D (ActD), a drug that induces DNA damage and apoptosis, and measured cell death via flow cytometry.
The results were clear:
- Overexpressing RFX5 or YWHAQ reduced apoptosis: HepG2 cells with extra RFX5 or YWHAQ had 50% fewer dead cells after ActD treatment than control cells.
- Knocking down RFX5 increased apoptosis: RFX5-depleted cells had 2–3x more dead cells than controls.
- YWHAQ rescued RFX5 loss: When the team overexpressed YWHAQ in RFX5-knockdown cells, apoptosis dropped back to normal levels.
How does this work? The team looked at the p53 pathway—a key “tumor suppressor” network that triggers apoptosis when cells are damaged. They found that RFX5 and YWHAQ both reduce levels of two pro-death proteins:
- p53: A “guardian of the genome” that activates apoptosis when DNA is damaged.
- Bax: A protein that punctures mitochondria (cell “powerhouses”) to start the death process.
When RFX5 was overexpressed, p53 and Bax levels dropped; when RFX5 was knocked down, they rose. Critically, overexpressing YWHAQ in RFX5-depleted cells reversed this effect—proving YWHAQ is the direct mediator of RFX5’s anti-apoptotic activity.
What This Means for HCC Research
The study’s biggest takeaway is that RFX5 and YWHAQ form a oncogenic pathway (cancer-causing loop) in HCC: RFX5 turns on YWHAQ, which blocks p53/Bax-mediated apoptosis, allowing HCC cells to survive and grow. This aligns with previous research on 14-3-3 proteins—YWHAQ’s family—which are known to promote cancer by inhibiting tumor suppressors. For example, YWHAQ is overexpressed in breast cancer and linked to chemotherapy resistance, and other 14-3-3 proteins sequester Bax in the cytoplasm to prevent cell death.
But the study also has limitations:
- Small sample size: The IHC analysis included only 128 HCC patients, and YWHAQ’s link to clinical outcomes (like tumor stage or metastasis) wasn’t fully explored.
- HBV/HCV focus: Most HCC cases are linked to hepatitis B or C, but the team didn’t analyze RFX5’s role in virus-associated tumors.
- YWHAQ validation: The team didn’t have enough tissue samples to confirm YWHAQ’s protein levels correlate with prognosis via IHC.
Conclusion
This research identifies RFX5 as a putative driver gene in HCC—meaning it’s not just associated with cancer, but actively causes it. By targeting YWHAQ and blocking apoptosis, RFX5 helps HCC cells evade the body’s natural defenses and standard therapies. For patients, this could mean new treatment targets: drugs that inhibit RFX5 or YWHAQ might sensitize HCC cells to apoptosis, making them more vulnerable to chemotherapy or immunotherapy.
The study also adds to a growing body of work on 14-3-3 proteins in cancer, highlighting their role beyond the immune system. As the team notes, “RFX5 might function together with its transactivated target genes as a transcription factor in HCC, but not only by itself.” Future research will need to explore how RFX5 interacts with other pathways (like Wnt/β-catenin or PI3K/AKT, which are often dysregulated in HCC) and whether RFX5/YWHAQ can serve as biomarkers for patient prognosis.
For now, this study is a critical step forward in understanding HCC biology—and a reminder that even “well-known” proteins can have unexpected roles in cancer.
This study was published in the Chinese Medical Journal in 2019 by Dong-Bo Chen, Yang-Jing Zhao, Xue-Yan Wang, and colleagues. You can access the full paper via doi.org/10.1097/CM9.0000000000000296.
Was this helpful?
0 / 0